Drugs / placental-derived SVF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06373809 | Oct 2021 → Mar 2024 | diabetic neuropathy, ulcer of lower limbs | Michael H Carstens | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | placental-derived SVF | “Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients” NCT06373809 ↗ |
| Known as | PDSC | “This is an initial dose escalation safety and exploratory efficacy study to treat two groups of subjects with critically sized diabetic wounds and diabetic neuropathy using...” NCT06373809 ↗ |
| Modality | Cell therapy | “using placental-derived stem cells (PDSC) transplanted by injection into soft tissues of the lower limb” NCT06373809 ↗ |
| Route | Subcutaneous | “Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients” NCT06373809 ↗ |